Neurogene Third-Quarter 2026 Net Loss Widens to $29 Million

The Tip Desk · November 12, 2026 · 3 min read

Neurogene's third-quarter 2026 net loss widened to $29.0 million from $21.0 million a year earlier. Cash, cash equivalents and short-term investments stood at $359.7 million as of September 30, 2026, after an oversubscribed offering of about $144 million in gross proceeds, with operations expected to be funded into the first quarter of 2029.

Neurogene Inc. (NGNE), a clinical-stage company developing genetic medicines for rare neurological diseases, reported a net loss of $29.0 million for the three months ended September 30, 2026, compared with $21.0 million a year earlier. Cash, cash equivalents and short-term investments were $359.7 million as of September 30, 2026, after an oversubscribed public follow-on offering of about $144 million in gross proceeds. The company said the cash is expected to fund planned operations into the first quarter of 2029.

The balance-sheet update followed the second-quarter close, when cash, cash equivalents and short-term investments were $225.4 million as of June 30, 2026. Neurogene said the offering, which included full exercise of the underwriters’ option, extended the cash runway into the first quarter of 2029.

Research and development expenses were $23.5 million for the three months ended September 30, 2026, compared with $17.2 million a year earlier. The company said the increase was primarily driven by higher costs associated with the development of NGN-401, including Rett syndrome clinical trial activities and chemistry, manufacturing and controls work, as well as higher employee-related expenses from an increase in R&D headcount and increased non-cash stock-based compensation. The increase was partially offset by lower spending on the CLN5 Batten disease program.

General and administrative expenses were $8.9 million for the three months ended September 30, 2026, compared with $6.6 million for the three months ended September 30, 2025. Neurogene said the increase was primarily driven by higher non-cash stock-based compensation, including performance-based stock unit awards after specified corporate milestones, as well as corporate and pre-commercial activities, higher employee-related expenses and professional fees.

The Embolden registrational trial of NGN-401 for Rett syndrome was overenrolled due to strong demand from the Rett syndrome community. Neurogene elected to include all 25 participants dosed in the primary efficacy analysis. The corresponding threshold for success to reject the null hypothesis is 9 of 25 participants (36%). The company said all other previously aligned key elements of the trial design remain unchanged. Dosing of 25 participants had been completed in the prior quarter.

Topline data from Embolden remain anticipated in the second half of 2027, unchanged from the prior-quarter outlook.

NGN-401 at the 1E15 vg dose has been generally well-tolerated in the Phase 1/2 trial and Embolden (N=35) as of November 8, 2026.

The company said it remains on track to complete Process Performance Qualification runs by the end of 2026 to support a planned Biologics License Application submission, after initiating the PPQ campaign in July 2026.

Founder and Chief Executive Officer Rachel McMinn said the company continued to execute across all aspects of the NGN-401 program as it advances toward potential commercialization, and that it is progressing key BLA and commercial-readiness activities.

Neurogene presented an encore of long-term Phase 1/2 data as of the June 16, 2026 cutoff at the 55th Child Neurology Society Annual Meeting, and presented preclinical data at the European Society of Gene and Cell Therapy 2026 Annual Congress on rapid onset and durable expression of full-length MECP2 with a single-stranded AAV construct.